A double-blind, crossover trial comparing nedocromil sodium with placebo in bronchial antigen challenge tests

Abstract

Ten asthmatic patients were randomly allocated to receive nedocromil sodium 0.5, 1.0 or 2.0 mg or matching placebo 3 h before antigen challenge in a double-blind study to investigate the efficacy of nedocromil sodium in protecting against the immediate bronchoconstrictor response following antigen challenge. All three nedocromil sodium dosages were found to be significantly more effective than placebo. The 1.0 and 2.0 mg doses, between which there was no significant difference, were each more effective than the 0.5 mg dose in inhibiting antigen-induced bronchoconstriction. No unusual symptoms or adverse reactions were reported.